[go: up one dir, main page]

CA2421723A1 - Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci - Google Patents

Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci Download PDF

Info

Publication number
CA2421723A1
CA2421723A1 CA002421723A CA2421723A CA2421723A1 CA 2421723 A1 CA2421723 A1 CA 2421723A1 CA 002421723 A CA002421723 A CA 002421723A CA 2421723 A CA2421723 A CA 2421723A CA 2421723 A1 CA2421723 A1 CA 2421723A1
Authority
CA
Canada
Prior art keywords
stat3
cells
compound
leu
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002421723A
Other languages
English (en)
Inventor
Hua Yu
Drew Pardoll
Richard Jove
William Dalton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
University of South Florida St Petersburg
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2421723A1 publication Critical patent/CA2421723A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés de modulation, c.-à-d. ayant une action agoniste ou antagoniste sur l'activité de signalisation de Stat3 (transducteur de signal et activateur de transcription3), utiles en thérapie génique. L'inhibition et/ou l'activation de la signalisation de Stat3 constitue une méthode efficace de modulation de l'angiogenèse et de la réaction immunitaire pour traiter et/ou prévenir l'inflammation, les infections, les affections immunitaires et l'ischémie.
CA002421723A 2000-09-08 2001-09-10 Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci Abandoned CA2421723A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23121200P 2000-09-08 2000-09-08
US60/231,212 2000-09-08
PCT/US2001/028254 WO2002020032A1 (fr) 2000-09-08 2001-09-10 Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci

Publications (1)

Publication Number Publication Date
CA2421723A1 true CA2421723A1 (fr) 2002-03-14

Family

ID=22868214

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002421723A Abandoned CA2421723A1 (fr) 2000-09-08 2001-09-10 Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci

Country Status (3)

Country Link
EP (1) EP1324763A4 (fr)
CA (1) CA2421723A1 (fr)
WO (1) WO2002020032A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044774A2 (fr) 1999-01-27 2000-08-03 The University Of South Florida Inhibition de la transduction du signal par la stat3 pour une therapie anticancereuse chez l'homme
US7638122B2 (en) * 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US7951374B2 (en) 2004-12-14 2011-05-31 University Of South Florida Methods for inhibiting STAT3 signaling in immune cells
US8841257B2 (en) 2009-04-10 2014-09-23 Board Of Regents, The University Of Texas System Inhibitors of STAT3 and uses thereof
JP7312695B2 (ja) * 2016-07-19 2023-07-21 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｓｔａｔ３を標的とする腫瘍溶解性ウイルス

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044774A2 (fr) * 1999-01-27 2000-08-03 The University Of South Florida Inhibition de la transduction du signal par la stat3 pour une therapie anticancereuse chez l'homme
US6159694A (en) * 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
US6235873B1 (en) * 1999-07-31 2001-05-22 The Rockefeller University Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes

Also Published As

Publication number Publication date
EP1324763A4 (fr) 2007-10-31
EP1324763A1 (fr) 2003-07-09
WO2002020032A1 (fr) 2002-03-14
WO2002020032A9 (fr) 2003-03-20

Similar Documents

Publication Publication Date Title
US20090227489A1 (en) STAT3 Agonists and Antagonists and Therapeutic Uses Thereof
Ghoreschi et al. Janus kinases in immune cell signaling
Soilu-Hänninen et al. Nerve growth factor signaling through p75 induces apoptosis in Schwann cells via a Bcl-2-independent pathway
Takayanagi et al. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts
US6475987B1 (en) Tall-1 receptor homologues
Sennello et al. Lrp5/β-catenin signaling controls lung macrophage differentiation and inhibits resolution of fibrosis
US20210079392A1 (en) Inhibition of mir-22 mirna by apt-110
US20040224389A1 (en) Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
JP2006505266A (ja) 幹細胞の増幅因子
US20090038022A1 (en) IGF-1 Novel peptides
MX2014000872A (es) Modulacion de quimiocina selectiva de tumor.
US6312684B1 (en) Method of inducing resistance to tumor growth
JP2003512304A (ja) 医薬組成物および分泌フリズル化関連タンパクを用いる方法
JP2005504010A (ja) 成長ホルモンおよびｆｏｘｍ１ｂを用いた肝臓疾患および肝臓損傷の処置方法
CA2421723A1 (fr) Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci
HUP0201966A2 (en) Methods of treatment and drug screening methods
EP3884055B1 (fr) Construction de gènes suicides doubles et inductibles et son utilisation dans la thérapie génique
US20040109844A1 (en) Methods of treating age-related defects and diseases
WO2003061684A2 (fr) Nouvelles compositions pharmaceutiques pour le traitement d'une tumeur
JPH11514884A (ja) 腫瘍にあるサイクリンｇ１の発現
Yakes et al. CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis
JP2002533402A (ja) 癌を処置するためおよび樹状細胞の走化性を媒介するための方法
JP4252446B2 (ja) Ａｂｉｎにより媒介される肝炎防護
JP2007516984A (ja) 治療用物質およびそのための用途
US6268350B1 (en) Polynucleotides for inhibiting metastasis and tumor cell growth

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20110110